Australia is experience potentially transformative therapy for excess weight: Retatrutide. This new dual agonist – targeting on both GLP-1 and GIP receptors – demonstrates significant outcomes in clinical studies, pointing to meaningful decreases in body fat. While approval hasn't occurred with Australian regulators, a number of Australians bat